March 23, 2022
ONK Therapeutics Appoints Dr. Allan Reine as Independent Non-Executive Director
ONK Therapeutics has appointed Allan Reine as independent Non-Executive Director to its Board.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
March 22, 2022
Torsten Buergermeister Joins VERAXA Biotech GmbH as Chief Financial Officer
Torsten Buergermeister has been appointed Chief Financial Officer (CFO) of VERAXA Biotech, based in Heidelberg, Germany.
March 22, 2022
Moderna Makes Annual Booster Combo Respiratory Vaccine Targeting all Four Endemic HCoV
Moderna, Inc. (NASDAQ:MRNA) is expanding its mRNA pipeline with two new development programs. This announcement reflects the company’s commitment to expanding its portfolio by building on Moderna’s experience with Spikevax, its COVID-19 vaccine.
March 22, 2022
Glenmark Pharmaceuticals Receives ANDA Approval for Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg
Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for…
March 22, 2022
Catalent Biologics Completes $30 Million Project for Biopharmaceutical Development and Drug Product Manufacturing in France
Catalent has completed a $30 million (€27 million) project at its facility in Limoges, France, to transform the site into a European center of excellence for biopharmaceutical development, drug product fill/finish services, and packaging.
March 22, 2022
ReNeuron Announces Board Changes
ReNeuron Group plc (AIM: RENE), a UK-based Stem Cell and Exosomes zechnologies company, announces that Dr Tim Corn and Mark Evans have resigned as Non-Executive Directors of the Company and that Martin Walton has been appointed as a Non-Executive Director, all with immediate effect.
March 21, 2022
Leica Microsystems Introduces its New Coral Cryo Workflow Solution
Leica Microsystems has introduced the new Coral Cryo workflow solution. The workflow solution enables researchers to increase their success rate…
March 21, 2022
Bristol Myers Squibb to Present its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session
Bristol Myers Squibb has announced that data from its cardiovascular portfolio will be presented at the American College of Cardiology’s 71st Annual Scientific Session, taking place in Washington, DC, and virtually, from April 2-4, 2022.
March 18, 2022
Moderna asks FDA’s approval for the 4th Dose Covid-19 Vaccine
Moderna has submitted a request to the U.S. Food and Drug Administration (FDA) for an amendment to the emergency use authorization (EUA) to allow for a fourth dose of its COVID-19 vaccine (mRNA-1273) in adults 18 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines.
March 18, 2022
Gamifant Approved in China for the Treatment of Primary HLH
Sobi has announced that the National Medical Products Administration of China (NMPA) has approved Gamifant (emapalumab) for use in China. The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy.